Trial reportEvidence-based mental health2021
Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
Trial report in Evidence-based mental health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.Archives of pharmacal research · 2026Pooled it
- Efficacy of digital cognitive stimulation therapy for people with dementia: a systematic review and meta-analysis.BMC geriatrics · 2026Pooled it
- Unlocking the Potential of Repetitive Transcranial Magnetic Stimulation in Alzheimer's Disease: A Meta-Analysis of Randomized Clinical Trials to Optimize Intervention Strategies.Journal of Alzheimer's disease : JAD · 2024Pooled it
- Mapping new pharmacological interventions for cognitive function in Alzheimer's disease: a systematic review of randomized clinical trials.Frontiers in pharmacology · 2023Pooled it
- Limitations of MMSE in Cognitive Assessment: Revealing Latent Risk via Structural Brain Atrophy.Life (Basel, Switzerland) · 2026Article
- Predicting rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment.Communications medicine · 2026Article
- Characterizing heterogeneity in Alzheimer's disease progression: a semiparametric model.Scientific reports · 2025Article
- Review
- Validity, reliability, measurement invariance, and equipercentile linking of the depression anxiety stress scale-21 in the youth population in Singapore.Frontiers in psychology · 2025Article
- Carpe diem.Evidence-based mental health · 2022Article
- Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.European journal of clinical pharmacology · 2022Review
- Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age.Evidence-based mental health · 2022Article
- The Effects of High-Intensity Functional Training on Cognition in Older Adults with Cognitive Impairment: A Systematic Review.Healthcare (Basel, Switzerland) · 2022Review
- Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model.BMC medicine · 2022Article
- How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D.Evidence-based mental health · 2021Article
- Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil.European psychiatry : the journal of the Association of European Psychiatrists · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Severe Impairment Battery (SIB) are widely used rating scales to assess cognition in Alzheimer's disease.
objectiveTo understand the correspondence between these rating scales, we aimed to examine the linkage of MMSE with the ADAS-Cog and SIB total and change scores.
methodsWe used individual-level data on participants with Alzheimer's disease (n=2925) from five pivotal clinical trials of donepezil. Data were collected at baseline and scheduled visits for up to 6 months. We used equipercentile linking to identify the correspondence between simultaneous measurements of MMSE with ADAS-Cog, and SIB total and change ratings.
findingsSpearman's correlation coefficients were of strong magnitude between the MMSE total score and the ADAS-Cog (rs from -0.82 to -0.87; p<0.05) and SIB total scores (rs from 0.70 to 0.75; p<0.05). Weaker correlations between the change scores were observed between the MMSE change score and the ADAS-Cog (week 1: r=-0.11, p=0.18; rs thereafter: -0.28 to -0.45; p<0.05) and SIB change scores (rs from 0.31 to 0.44; p<0.05). Linking suggested that the MMSE total scores were sensitive to moderate and severe cognitive impairment levels. Despite weak to moderate correlations for the change scores, moderate change levels linked well, indicating ceiling and floor effects.
conclusionsThe current results can be used in meta-analyses, data harmonisation and may contribute to increasing statistical power when pooling data from multiple sources. CLINICAL IMPLICATIONS: The current study results help clinicians to understand these cognitive rating scale scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.